The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Paraneoplastic neurological syndromes
Open accessAbstract
Paraneoplastic neurological syndromes (PNS) can be defined as remote effects of cancer that are not caused by the tumor and its metastasis, or by infection, ischemia or metabolic disruptions. PNS are rare, affecting less than 1/10,000 patients with cancer. Only the Lambert-Eaton myasthenic syndrome is relatively frequent, occurring in about 1% of patients with small cell lung cancer. PNS can affect any part of the central and peripheral nervous system, the neuromuscular junction, and muscle. They can be isolated or occur in association. In most patients, the neurological disorder develops before the cancer becomes clinically overt and the patient is referred to the neurologist who has the charge of identifying a neurological disorder as paraneoplastic. PNS are usually severely disabling. The most common PNS are Lambert-Eaton myasthenic syndrome (LEMS), subacute cerebellar ataxia, limbic encephalitis (LE), opsoclonus-myoclonus (OM), retinopathies (cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR), Stiff-Person syndrome (SPS), chronic gastrointestinal pseudoobstruction (CGP), sensory neuronopathy (SSN), encephalomyelitis (EM) and dermatomyositis. PNS are caused by autoimmune processes triggered by the cancer and directed against antigens common to both the cancer and the nervous system, designated as onconeural antigens. Due to their high specificity (> 90%), the best way to diagnose a neurological disorder as paraneoplastic is to identify one of the well-characterized anti-onconeural protein antibodies in the patient's serum. In addition, as these antibodies are associated with a restricted range of cancers, they can guide the search for the underlying tumor at a stage when it is frequently not clinically overt. This is a critical point as, to date, the best way to stabilize PNS is to treat the cancer as soon as possible. Unfortunately, about one-third of patients do not have detectable antibodies and 5% to 10% have an atypical antibody that is not well-characterized. As PNS are believed to be immune-mediated, suppression of the immune response represents another treatment approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Functioning and Well-being of Depressed Patients: Results From the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.1989.03430070062031 · Cited by 2,130
Recommended diagnostic criteria for paraneoplastic neurological syndromes
Graus, F. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.034447 · Cited by 1,610
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study
Hill, C. L., Zhang, Y., Sigurgeirsson, B., Pukkala, E., Mellemkjaer, L., Airio, A., Evans, S. R., & Felson, D. T. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03540-6 · Cited by 1,191
Gultekin, S. H. (2000) · Brain · doi:10.1093/brain/123.7.1481 · Cited by 1,123
Paraneoplastic Syndromes Involving the Nervous System
Darnell, R. B., & Posner, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023009 · Cited by 1,062
Vincent, A., Buckley, C., Schott, J. M., Baker, I., Dewar, B., Detert, N., Clover, L., Parkinson, A., Bien, C. G., Omer, S., et al. (2004) · Brain · doi:10.1093/brain/awh077 · Cited by 1,038
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients
Graus, F. (2001) · Brain · doi:10.1093/brain/124.6.1138 · Cited by 897
Dalmau, J., Graus, F., Rosenblum, M. K., & Posner, J. B. (1992) · MEDICINE · doi:10.1097/00005792-199203000-00001 · Cited by 819
Clinical analysis of anti-Ma2-associated encephalitis
Dalmau, J. (2004) · Brain · doi:10.1093/brain/awh203 · Cited by 771
THE LAMBERT-EATON MYASTHENIC SYNDROME: A REVIEW OF 50 CASES
O'NEILL, J. H., MURRAY, N. M. F., & NEWSOM-DAVIS, J. (1988) · Brain · doi:10.1093/brain/111.3.577 · Cited by 686
Cited by
Venkatesan, A., Tunkel, A. R., Bloch, K. C., Lauring, A. S., Sejvar, J., Bitnun, A., Stahl, J.-P., Mailles, A., Drebot, M., Rupprecht, C. E., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit458 · Cited by 1,197
Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
Pelosof, L. C., & Gerber, D. E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0099 · Cited by 773
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
Graus, F., Vogrig, A., Muñiz-Castrillo, S., Antoine, J.-C. G., Desestret, V., Dubey, D., Giometto, B., Irani, S. R., Joubert, B., Leypoldt, F., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001014 · Cited by 759
Self-citation
Metadata
- Authors
- Honnorat, J., & Antoine, J.-C.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2007-05-04
- Volume
- 2
- Issue
- 1
- Pages
- 22-22
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W3022314034
- Cited by
- 357
- References
- 59
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Paraneoplastic neurological syndromes. https://app.cochat.ai/papers/10.1186/1750-1172-2-22
- The paper
- Honnorat, J., & Antoine, J.-C. (2007). Paraneoplastic neurological syndromes. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-2-22
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.